ES2153927T3 - Intermedios de dioxolano. - Google Patents

Intermedios de dioxolano.

Info

Publication number
ES2153927T3
ES2153927T3 ES96115235T ES96115235T ES2153927T3 ES 2153927 T3 ES2153927 T3 ES 2153927T3 ES 96115235 T ES96115235 T ES 96115235T ES 96115235 T ES96115235 T ES 96115235T ES 2153927 T3 ES2153927 T3 ES 2153927T3
Authority
ES
Spain
Prior art keywords
intermediates
dioxolan
substituted phenyl
hydrogen
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96115235T
Other languages
English (en)
Inventor
Jonathan Philip Chiros Dickens
Michael John Crimmin
Raymond Paul Beckett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
British Biotech Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Biotech Pharmaceuticals Ltd filed Critical British Biotech Pharmaceuticals Ltd
Application granted granted Critical
Publication of ES2153927T3 publication Critical patent/ES2153927T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPUESTOS DE FORMULA (V): EN DONDE R 2 REPRESENTA UN GRUPO R{SUB,6}-A EN DONDE A REPRESENTA UNA CADENA HIDROCARBONADA SATURADA O INSATURADA LINEAL O RAMIFICADA DIVALENTE DE MAS DE 6 ATOMOS DE C LOS CUALES PUEDEN ESTAR INTERRUMPIDOS POR UN ATOMO DE O O S, Y R{SUB,6} REPRESENTA HIDROGENO O UN GRUPO FENILO, CICLOALQUILO O CICLOALQUENILO OPCIONALMENTE SUSTITUIDO; Y LOS GRUPOS R{SUB,12} Y R{SUB,13} SON HIDROGENO, ALQUILO, FENILO O FENILO SUSTITUIDO Y DERIVADOS ACTIVADOS DE ELLOS QUE SON UTILES COMO INTERMEDIOS EN LA PREPARACION DE INHIBIDORES DE MATRIZ METALOPROTEINASA.
ES96115235T 1992-07-23 1993-07-23 Intermedios de dioxolano. Expired - Lifetime ES2153927T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929215665A GB9215665D0 (en) 1992-07-23 1992-07-23 Compounds

Publications (1)

Publication Number Publication Date
ES2153927T3 true ES2153927T3 (es) 2001-03-16

Family

ID=10719178

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96115235T Expired - Lifetime ES2153927T3 (es) 1992-07-23 1993-07-23 Intermedios de dioxolano.

Country Status (26)

Country Link
US (3) US5643964A (es)
EP (3) EP0651739B1 (es)
JP (3) JP2768554B2 (es)
KR (1) KR100205710B1 (es)
AT (3) ATE198331T1 (es)
AU (2) AU4715293A (es)
CA (1) CA2140626C (es)
CY (1) CY1944A (es)
CZ (1) CZ285896B6 (es)
DE (5) DE4393452T1 (es)
DK (2) DK0651739T3 (es)
ES (1) ES2153927T3 (es)
FI (1) FI114549B (es)
GB (4) GB9215665D0 (es)
GR (2) GR3023522T3 (es)
HK (1) HK149396A (es)
HU (2) HU220625B1 (es)
NO (1) NO303221B1 (es)
NZ (1) NZ254862A (es)
PL (1) PL174279B1 (es)
PT (1) PT754688E (es)
RU (1) RU2126791C1 (es)
SK (1) SK281240B6 (es)
UA (1) UA29450C2 (es)
WO (2) WO1994002446A1 (es)
ZA (2) ZA935352B (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9307956D0 (en) * 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
ES2075798B1 (es) * 1993-08-18 1996-03-01 British Bio Technology Derivados de aminoacidos naturales como inhibidores de metaloproteinasas, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y el uso de dichos compuestos en medicina.
ES2075797B1 (es) * 1993-08-18 1996-05-16 British Bio Technology Derivados de acidos hidroxamicos terapeuticamente activos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y el uso de dichos compuestos en medicina.
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
EP0715619A4 (en) * 1993-08-23 1997-03-19 Immunex Corp INHIBITORS OF TNF-ALPHA SECRETION
GB2299335B (en) * 1994-01-21 1997-12-17 British Biotech Pharm Hydroxamic acid derivatives as metalloproteinase inhibitors
GB9401129D0 (en) * 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
EP0905126B1 (en) * 1994-01-22 2002-12-04 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
GB9404046D0 (en) * 1994-03-03 1994-04-20 Smithkline Beecham Corp Novel compounds
GB9411088D0 (en) * 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives
GB9416897D0 (en) * 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5639746A (en) * 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
AU5002196A (en) * 1995-03-28 1996-10-16 Novo Nordisk A/S Immunosuppressive agents
US5691381A (en) * 1995-04-18 1997-11-25 The Dupont Merck Pharmaceutical Company Hydroxamic and carbocyclic acids as metalloprotease inhibitors
GB9507799D0 (en) * 1995-04-18 1995-05-31 British Biotech Pharm Metalloproteinase inhibitors
JP3156794B2 (ja) * 1995-04-25 2001-04-16 富士薬品工業株式会社 高水溶性メタロプロテイナーゼ阻害剤
CA2219973A1 (en) * 1995-05-10 1996-11-14 Chiroscience Limited Peptidyl compounds and their therapeutic use
GB9513331D0 (en) * 1995-06-30 1995-09-06 British Biotech Pharm Matrix metalloproteinase inhibitors
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
WO1997003966A1 (en) * 1995-07-19 1997-02-06 British Biotech Pharmaceuticals Limited N-(amino acid) substituted succinic acid amide derivatives as metalloproteinase inhibitors
GB2318353B (en) * 1995-07-20 1999-10-06 British Biotech Pharm Metalloproteinase inhibitors
GB9514867D0 (en) * 1995-07-20 1995-09-20 British Biotech Pharm Metalloproteinase inhibitors
US6281352B1 (en) 1995-11-14 2001-08-28 Dupont Pharmaceuticals Company Macrocyclic compounds as metalloprotease inhibitors
GB9523637D0 (en) * 1995-11-18 1996-01-17 British Biotech Pharm Synthesis of carboxylic acid derivatives
ES2172690T3 (es) * 1995-11-22 2002-10-01 Darwin Discovery Ltd Compuestos de mercaptoalquilpeptidil con un sustituyente de imidazol y su utilizacion como inhibidores de metaloproteinasas de matriz (mmp) y/o del factor de necrosis tumoral (tnf).
CZ292617B6 (cs) 1995-11-23 2003-11-12 British Biotech Pharmaceuticals Limited Inhibitory metaloproteinázy a farmaceutický prostředek
GB9609702D0 (en) 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
GB9609794D0 (en) * 1996-05-10 1996-07-17 Smithkline Beecham Plc Novel compounds
EP0925303B1 (en) * 1996-08-28 2002-10-23 The Procter & Gamble Company Phosphinic acid amides as matrix metalloprotease inhibitors
KR20000035917A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 1,4-헤테로고리성 메탈로프로테아제 저해제
KR20000035918A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 1,3-디헤테로시클릭 메탈로프로테아제 저해제
PT927183E (pt) * 1996-08-28 2004-12-31 Procter & Gamble Inibidores espirociclicos de metaloproteases
KR20000035920A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 헤테로고리성 메탈로프로테아제 저해제
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
BR9712019A (pt) 1996-09-10 1999-08-24 British Biotech Pharm Derivados de cidos hirox-mico citoest ticos
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
EP0971881A1 (en) * 1997-03-28 2000-01-19 AstraZeneca AB Process for the preparation of n-(3-hydroxy-succinyl)-amino acid derivatives
US6251913B1 (en) 1997-03-28 2001-06-26 Zeneca Limited Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor
US5883131A (en) * 1997-07-09 1999-03-16 Pfizer Inc. Cyclic sulfone derivatives
IL134273A0 (en) 1997-07-31 2001-04-30 Procter & Gamble Acyclic metalloprotease inhibitors
HRP980443A2 (en) 1997-08-18 1999-10-31 Carl P. Decicco Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
EP0897908A1 (de) 1997-08-19 1999-02-24 Roche Diagnostics GmbH 3-Aryl-Succinamido-Hydroxamsäuren, Prozesse zu ihrer Herstellung und diese Substanzen enthaltende Medikamente
US6403632B1 (en) 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
ZA988967B (en) * 1997-10-03 2000-04-03 Du Pont Pharm Co Lactam metalloprotease inhibitors.
AU2704599A (en) † 1997-11-14 1999-06-07 Procter & Gamble Company, The Disposable absorbent article with a skin care composition on an apertured top sheet
AU736511B2 (en) 1998-01-09 2001-07-26 Pfizer Inc. Matrix metalloprotease inhibitors
AU2594799A (en) 1998-02-11 1999-08-30 Du Pont Pharmaceuticals Company Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
BR9815717A (pt) * 1998-03-12 2000-11-07 British Biotech Pharm Agentes citostáticos
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
US6447693B1 (en) 1998-10-21 2002-09-10 W. R. Grace & Co.-Conn. Slurries of abrasive inorganic oxide particles and method for polishing copper containing surfaces
KR100748995B1 (ko) 1998-10-21 2007-08-13 더블유.알. 그레이스 앤드 캄파니-콘. 마모성 무기 산화물 입자의 슬러리 및 이러한 입자의마모성을 조절하기 위한 방법
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
WO2000051975A1 (en) 1999-03-03 2000-09-08 The Procter & Gamble Company Alkenyl- and alkynyl-containing metalloprotease inhibitors
EP1165500A1 (en) 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase
CA2361848A1 (en) 1999-04-02 2000-10-12 Dupont Pharmaceuticals Company Novel lactam inhibitors of matrix metalloproteinases, tnf-.alpha., and aggrecanase
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6297337B1 (en) 1999-05-19 2001-10-02 Pmd Holdings Corp. Bioadhesive polymer compositions
JP2001055327A (ja) * 1999-06-11 2001-02-27 Fuji Chemical Industries Ltd 新規なヒドロキサム酸誘導体を含む医薬
US6696456B1 (en) 1999-10-14 2004-02-24 The Procter & Gamble Company Beta disubstituted metalloprotease inhibitors
GB9929527D0 (en) * 1999-12-14 2000-02-09 Smithkline Beecham Plc Novel compounds
US6797820B2 (en) * 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
PL365444A1 (en) 2000-03-21 2005-01-10 The Procter & Gamble Company Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
AU2001245862A1 (en) 2000-03-21 2001-10-03 The Procter & Gamble Company Difluorobutyric acid metalloprotease inhibitors
US6620823B2 (en) 2000-07-11 2003-09-16 Bristol-Myers Squibb Pharme Company Lactam metalloprotease inhibitors
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
WO2002102791A1 (en) 2001-06-15 2002-12-27 Vicuron Pharmaceuticals Inc. Pyrrolidine bicyclic compounds
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
BRPI0407587A (pt) * 2003-02-18 2006-02-14 Pfizer inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam
US7846963B2 (en) 2003-05-17 2010-12-07 Korea Research Institute Of Bioscience And Biotechnology 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same
KR20110117731A (ko) 2003-05-30 2011-10-27 랜박시 래보러터리스 리미티드 치환된 피롤 유도체와 ｈｍｇ―ｃｏ 억제제로서의 이의 용도
AU2004263900A1 (en) 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
EP1737499A4 (en) 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE BY INHALATION OF LOW DOSES OF A PROTEASE HEMMER
AU2005266313B2 (en) 2004-07-26 2011-08-25 Merck Serono Sa N-hydroxyamide derivatives and use thereof
DE102005021806A1 (de) * 2005-05-04 2006-11-16 Lancaster Group Gmbh Verwendung von radikalfangenden Substanzen zur Behandlung von Zuständen mit erhöhter Hauttemperatur, insbesondere zur antipyretischen Behandlung
ATE518853T1 (de) 2005-08-12 2011-08-15 Schering Corp Verbindungen zur behandlung entzündlicher erkrankungen
AU2006313430B2 (en) 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
DE102007027772A1 (de) * 2007-06-16 2008-12-24 Ab Skf Anodnung zur Lagerung eines Maschinenteils
DE102007062199A1 (de) * 2007-12-21 2009-06-25 Evonik Degussa Gmbh 2-Methylthioethyl-substituierte Heterocyclen als Futtermitteladditive
IT1401253B1 (it) 2010-04-23 2013-07-18 Uni Degli Studi Carlo Bo Urbino Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.
FR3010076B1 (fr) * 2013-09-02 2016-12-23 Centre Nat De La Rech Scient - Cnrs - Inhibiteurs de metalloproteases, leurs procedes de preparation et leurs utilisations therapeutiques
WO2015107139A1 (en) * 2014-01-17 2015-07-23 Proyecto De Biomedicina Cima, S.L. Compounds for use as antifibrinolytic agents
US20210393632A1 (en) 2018-10-04 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas
IT202100023357A1 (it) 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL122359C (es) * 1964-03-06
IT1201443B (it) * 1985-07-31 1989-02-02 Zambon Spa Intermedi per la sintesi di acidi carbossilici
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
IT1198237B (it) * 1986-12-23 1988-12-21 Zambon Spa Intermedi per la sintesi di composti organici
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8919251D0 (en) * 1989-08-24 1989-10-04 British Bio Technology Compounds
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
CA2058797A1 (en) * 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
GB9307956D0 (en) * 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives

Also Published As

Publication number Publication date
FI950262A (fi) 1995-01-20
HU211287A9 (en) 1995-11-28
AU4715293A (en) 1994-02-14
JPH07509460A (ja) 1995-10-19
EP0754688B1 (en) 2000-12-27
GR3035510T3 (en) 2001-06-29
KR950702525A (ko) 1995-07-29
GB2287023B (en) 1996-02-14
RU2126791C1 (ru) 1999-02-27
EP0651739A1 (en) 1995-05-10
HUT70552A (en) 1995-10-30
GB2268933B (en) 1996-04-10
US5700838A (en) 1997-12-23
EP0754688A2 (en) 1997-01-22
DE69309686T2 (de) 1997-07-24
UA29450C2 (uk) 2000-11-15
GR3023522T3 (en) 1997-08-29
PL307171A1 (en) 1995-05-15
DE9321495U1 (de) 1998-09-10
GB9315222D0 (en) 1993-09-08
NZ254862A (en) 1996-02-27
US5912360A (en) 1999-06-15
DE69316367D1 (de) 1998-02-19
JP2768554B2 (ja) 1998-06-25
ZA935351B (en) 1994-02-14
CY1944A (en) 1997-05-16
NO303221B1 (no) 1998-06-15
PT754688E (pt) 2001-04-30
CZ15795A3 (en) 1995-10-18
EP0651738A1 (en) 1995-05-10
CA2140626C (en) 2002-09-03
EP0651738B1 (en) 1998-01-14
ATE151414T1 (de) 1997-04-15
RU95109920A (ru) 1996-10-27
CZ285896B6 (cs) 1999-11-17
JPH10204081A (ja) 1998-08-04
JPH07509459A (ja) 1995-10-19
HU9500202D0 (en) 1995-03-28
GB2268933A (en) 1994-01-26
EP0651739B1 (en) 1997-04-09
WO1994002446A1 (en) 1994-02-03
GB9500722D0 (en) 1995-03-08
DE69309686D1 (de) 1997-05-15
GB2287023A (en) 1995-09-06
DE4393452T1 (de) 1995-06-01
DE69316367T2 (de) 1998-06-10
FI114549B (fi) 2004-11-15
GB9315206D0 (en) 1993-09-08
EP0754688A3 (en) 1997-07-30
AU661410B2 (en) 1995-07-20
HU220625B1 (hu) 2002-03-28
NO950226D0 (no) 1995-01-20
US5643964A (en) 1997-07-01
SK281240B6 (sk) 2001-01-18
FI950262A0 (fi) 1995-01-20
SK7895A3 (en) 1995-07-11
HK149396A (en) 1996-08-16
AU4715393A (en) 1994-02-14
WO1994002447A1 (en) 1994-02-03
GB2268934A (en) 1994-01-26
DE69329804T2 (de) 2001-05-31
KR100205710B1 (ko) 1999-07-01
ATE198331T1 (de) 2001-01-15
JP2971053B2 (ja) 1999-11-02
DE69329804D1 (de) 2001-02-01
NO950226L (no) 1995-01-20
ATE162183T1 (de) 1998-01-15
DK0651739T3 (da) 1997-08-18
GB2268934B (en) 1996-01-24
DK0754688T3 (da) 2001-03-05
CA2140626A1 (en) 1994-02-03
ZA935352B (en) 1994-05-16
PL174279B1 (pl) 1998-07-31
GB9215665D0 (en) 1992-09-09

Similar Documents

Publication Publication Date Title
ES2153927T3 (es) Intermedios de dioxolano.
CY1109863T1 (el) Παραγωγα θειαζολης για χρηση ως αντιφλεγμονωδη
BR0116539A (pt) Derivados de piridona tendo uma atividade de ligação para o receptor 2 do tipo canabinóide
NO175253C (no) Forbindelse, anvendelse og preparat

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 754688

Country of ref document: ES